Tweet
Take your read length, and multiply it by the number of bases to get the total bases present in your dataset. So for a 1M SE @ 50bp, you have 50Mb. For 1M PE @50bpx50bp, you have 100Mb. If you look at one PE file (reads1), then you get 50Mb. Note, that the bfast file will contain both PE in the same file, so that would be 100Mb.
-
-
I'm sorry im still a little confused...Originally posted by nilshomer View Post
The formula i'm using for N is
N = (Genome size x Coverage) / ( RL1 + RL2)
So if my Genome size is 100Mb, Coverage is 10 and RL1 = RL2 = 50 (PE)
N = 100,000,000 x 10 / 100 = 10,000,000 read pairs
i.e *_10X_PE_1.fq = *_10x_PE_2.fq = 10,000,000 reads.
Now, if RL2=0, keeping coverage and genome size the same,
N = 100,000,000 x 10 / 50 = 20,000,000 read pairs or reads
i.e *_10X_SE_.fq1 = 20,000,000 reads and *_10X_SE_2.fq = 0 reads.
I Hope i'm right till here.
Furthermore, if i have already generated 20X coverage PE for the same genome,
N = 100,000,000 x 20 / 100 = 20,000,000 read pairs
i.e *_20X_PE_1.fq = *_20X_PE_2.fq = 20,000,000 reads.
Is it safe to assume that
either *_20X_PE_1.fq OR *_20X_PE_2.fq can be used as a substitute for *_10X_SE_.fq1 as both have the same number of reads?
Comment
-
The answer is yes.Comment
-
Thanks a lot
Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment